Novel Therapeutic Approaches to IBD: Considerations for Optimal Positioning in Clinical Practice

Saturday, December 14, 2019, 12:00 AM - Sunday, December 13, 2020, 11:58 PM

AMA PRA Category 1 Credits™ (1.25 hours), AMA PRA Category 1 Credits™ Designated (1.25 hours)


This enduring material was recorded from the live version.  

1. Describe the current understanding of IBD pathophysiology with respect to inflammatory pathways and potential therapeutic agents
2. Evaluate the mechanisms of action and available efficacy and safety data surrounding new and emerging therapies for the treatment of IBD
3. Integrate the latest clinical data into current and future personalized therapeutic strategies for the management of IBD

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Cincinnati, NACCME and Imedex are accredited by the ACCME to provide continuing medical education for physicians, and have collaborated to design and execute this activity.

For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.

The opinions expressed during this activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

No faculty are available for this activity at this time.

 This educational activity is supported by an educational grant from Janssen Pharmaceuticals, Inc.